(Q44793052)

6 December 2017

title

Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome (English)

1 reference

diffuse large B-cell lymphoma

6 December 2017

1 reference

1 reference

based on heuristic

inferred from title

author

Dennis D Weisenburger

17

object named as

Dennis D Weisenburger

1 reference

6 December 2017

15

Wing C Chan

1 reference

6 December 2017

11

James O Armitage

1 reference

6 December 2017

10

Julie M Vose

1 reference

6 December 2017

2

Bhavana J Dave

1 reference

6 December 2017

14

Timothy C Greiner

1 reference

6 December 2017

3

Anamarija M Perry

1 reference

6 December 2017

12

Patricia Aoun

1 reference

6 December 2017

8

Philip J Bierman

1 reference

6 December 2017

9

Robert G Bociek

1 reference

6 December 2017

Gabriel C Caponetti

1

1 reference

6 December 2017

Lynette M Smith

4

1 reference

6 December 2017

Smrati Jain

5

1 reference

6 December 2017

Paul N Meyer

6

1 reference

6 December 2017

Martin Bast

7

1 reference

6 December 2017

Kai Fu

13

1 reference

6 December 2017

Warren G Sanger

16

1 reference

6 December 2017

publication date

1 April 2015

1 reference

6 December 2017

1 reference

6 December 2017

volume

56

1 reference

6 December 2017

issue

11

1 reference

6 December 2017

page(s)

3082-3089

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

MYC and aggressive B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Double-hit B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

MYC/BCL2 double-hit high-grade B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

21 January 2018

Lymphoma cytogenetics

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1034699

10.3109/10428194.2015.1034699

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference